SCHEMBL4352240

SCHEMBL4352240

CC(O)c1cc(Cl)cc(NC(=S)NC(C)(C)C)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
ALDH1A1 P00352 5/20 0.44
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
HTT P42858 2/20 0.35
MAPT P10636 4/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350137 0.86 POLB (0.41) POLBALDH1A1GABRA1GABRB1HTT
SCHEMBL4355998 0.84 GABRA1 (0.41) POLBALDH1A1GABRA1GABRB1HTT
SCHEMBL4347844 0.83 KMT2A (0.43) ALDH1A1GABRA1GABRB1HTTMAPT
SCHEMBL4350857 0.82 ALDH1A1 (0.47) ALDH1A1GABRA1GABRB1HTTMAPT
SCHEMBL4344513 0.81 POLB (0.55) POLBALDH1A1HTTMAPTKDM4E
SCHEMBL4345457 0.80 CNR1 (0.46) ALDH1A1HTTMAPTKDM4EGAA
SCHEMBL4344612 0.78 ALDH1A1 (0.51) ALDH1A1HTTMAPTGAASMN1; SMN2
SCHEMBL4349891 0.78 HTT (0.41) POLBALDH1A1HTTMAPTKDM4E
SCHEMBL27761077 0.76 SMN1; SMN2 (0.49) POLBALDH1A1HTTMAPTGAA
SCHEMBL4354224 0.76 KMT2A (0.55) ALDH1A1MAPTGAASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 POLB 3571/4885ALDH1A1 2565/4885GABRA1 357/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 POLB 2402/4885ALDH1A1 2767/4885GABRA1 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.